Related Experiment Videos
Cellular replacement therapy for neurologic disorders: potential of genetically engineered cells
1Department of Neurosciences, University of California, San Diego, La Jolla 92093.
Journal of Cellular Biochemistry
|March 1, 1991
Summary
Genetically engineered skin fibroblasts offer a promising alternative for Parkinson's disease treatment. These modified cells, when grafted into the brain, survived and showed therapeutic effects in a rat model.
Area of Science:
- Neuroscience
- Cell Biology
- Gene Therapy
Background:
- Neural transplantation is a therapeutic strategy for Parkinson's disease, with graft metabolite release being a key mechanism.
- Ethical concerns and immune rejection complicate fetal tissue use, while autografting adult tissue suffers from poor cell survival.
- Genetically engineered cells present a viable alternative for donor cells in neural transplantation.
Purpose of the Study:
- To investigate the potential of primary skin fibroblasts as donor cells for intracerebral grafting in Parkinson's disease models.
- To assess the survival, in situ persistence, and therapeutic efficacy of genetically modified fibroblasts in the brain.
Main Methods:
- Primary skin fibroblasts were genetically engineered to express therapeutic genes, including those for L-dopa production.
- These modified fibroblasts were grafted into the denervated striatum of a rat model of Parkinson's disease.
- Cell survival, gene expression, and behavioral effects were monitored post-transplantation.
Main Results:
- Primary skin fibroblasts demonstrated survival and remained in situ within the brain after grafting.
- Successful introduction and expression of multiple genes (nerve growth factor, tyrosine hydroxylase, glutamic acid decarboxylase, choline acetyltransferase) were achieved.
- L-dopa-secreting fibroblasts showed a behavioral effect in the Parkinson's disease rat model for up to 8 weeks.
Conclusions:
- Primary skin fibroblasts are a suitable cell source for intracerebral grafting and gene therapy for Parkinson's disease.
- Further research should focus on optimizing gene transfer, transgene expression, and fibroblast survival in the brain to enhance therapeutic outcomes.